US 12,239,643 B2
Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases
Natsuki Ishida, Yokohama (JP); Yuji Tabata, Yokohama (JP); Takashi Matsuhira, Yokohama (JP); Keiji Tamura, Yokohama (JP); Takeru Yamakawa, Tokyo (JP); Satoshi Isshiki, Odawara (JP); Yoshinari Wakiyama, Odawara (JP); and Shohei Ouchi, Yokohama (JP)
Assigned to MEIJI SEIKA PHARMA CO., LTD., Tokyo (JP)
Appl. No. 17/255,560
Filed by MEIJI SEIKA PHARMA CO., LTD., Tokyo (JP)
PCT Filed Jun. 27, 2019, PCT No. PCT/JP2019/025526
§ 371(c)(1), (2) Date Dec. 23, 2020,
PCT Pub. No. WO2020/004521, PCT Pub. Date Jan. 2, 2020.
Claims priority of application No. 2018-121442 (JP), filed on Jun. 27, 2018.
Prior Publication US 2021/0315892 A1, Oct. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4995 (2006.01); A61K 31/439 (2006.01); A61K 31/5386 (2006.01); A61P 17/04 (2006.01); A61P 19/02 (2006.01); A61P 19/04 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 37/06 (2006.01)
CPC A61K 31/4995 (2013.01) [A61K 31/439 (2013.01); A61K 31/5386 (2013.01); A61P 17/04 (2018.01); A61P 19/02 (2018.01); A61P 19/04 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 37/06 (2018.01)] 7 Claims
 
1. A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient,

OG Complex Work Unit Chemistry
In the formula (1),
R1 and R2 may be the same or different and each represents a hydrogen atom; a halogen atom; a hydroxyl group; a carboxy group; a cyano group; an optionally substituted C1-6 alkyl group; an optionally substituted C3-7 cycloalkyl group; an optionally substituted C6-10 monocyclic or polycyclic aryl group; an optionally substituted C7-11 monocyclic or polycyclic aralkyl group; an optionally substituted 4- to 10-membered monocyclic or bicyclic aromatic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; an optionally substituted 4- to 10-membered monocyclic or bicyclic nonaromatic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; an optionally substituted di-C1-6 alkyl amino group; an optionally substituted C3-7 cycloalkyl amino group; an optionally substituted C1-6 acylamino group; an optionally substituted C1-6 alkyloxy group; an optionally substituted C2-6 alkenyloxy group; an optionally substituted C1-6 alkyloxy-C1-6 alkyl group; an optionally substituted C3-7 cycloalkyloxy group; an optionally substituted C6-10 monocyclic or polycyclic aryloxy group; an optionally substituted C7-11 monocyclic or polycyclic aralkyloxy group; an optionally substituted 4- to 10-membered monocyclic or bicyclic aromatic heterocyclyloxy group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; an optionally substituted 4- to 10-membered monocyclic or bicyclic nonaromatic heterocyclyloxy group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; an optionally substituted C1-6 alkylthio group; an optionally substituted C1-6 alkylsulfonyl group; an optionally substituted C1-6 alkylsulfinyl group; an optionally substituted mono-C1-6 alkylsulfamoyl group; an optionally substituted di-C1-6 alkylsulfamoyl group wherein two C1-6 alkyl groups in the di-C1-6 alkylsulfamoyl group may form a pyrrolidin-1-yl group or a morpholino group with an adjacent nitrogen atom; a sulfamoyl group; an optionally substituted C1-6 alkylcarbonyl group; an optionally substituted 1-(C1-6 alkyloxy)imino-C1-6 alkyl group; an aminocarbonyl group; an optionally substituted mono-C1-6 alkylaminocarbonyl group; an optionally substituted di-C1-6 alkylaminocarbonyl group; an optionally substituted C3-7 cycloalkylaminocarbonyl group; an optionally substituted C7-11 monocyclic or polycyclic aralkylaminocarbonyl group; an optionally substituted C1-6 alkyloxycarbonyl group; or an optionally substituted hydroxyaminocarbonyl group;
R3 represents a hydrogen atom;
R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom;
X represents a group represented by the following formula: —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, or —CH2—O—CH2—, and
Z represents a hydrogen atom or a hydroxyl group.